• info@betterlife-technologies.com
  • + 202 22576731
  • 09:00 – 17:00 Saturday to Thursday

Biosensors International Group

Biosensors International Group

The Biosensors International Group has operations worldwide and is headquartered in Singapore. The European headquarters are located in Morges (Switzerland). With the combination of a direct sales network and distributors across the world, Biosensors is dedicated to serving the needs of the healthcare community and is committed to, the support of bona fide medical education, advancing the progress of medical science and improving patient care, through training courses, scientific summits and symposia and related events on a regular basis, both in international forums and at national level. Biosensors also participate in some of the major cardiology congresses throughout the world - doing so in a way that complies with all ethical and legal requirements.

Products

Biosensors International operates globally, offering interventional devices and solutions for patients living with Coronary Artery Disease. We are proud of our track record and our continued innovation in the development of next-generation medical technologies, that make a difference to patients’ lives around the world. Our global commercial teams together with a strong network of distributors, present and deliver our products where they can be of the greatest benefit. Complementing our established cardiovascular presence, our endovascular devices are offering more solutions for patients whose lives we touch. Pioneering spirit led to Biosensors International developing its own Proprietary Technology in Biolimus A9™. The only limus drug designed specifically for coronary stent applications. BA9™ coated DES and DCS platforms, started a new stent generation that provides treatment solutions for previously neglected patients.

BioMatrix NeoFlex

When it comes to biodegradable polymer technology, Biosensors has developed the highest level of expertise and delivered the best results in terms of safety and efficacy. BioMatrix NeoFlex is a stainless steel DES with an enhanced stent delivery system brings exceptional performance in complex lesions and challenging anatomies. With the LEADERS1 trial 5-year results BioMatrix NeoFlex™ achieved Gold Standard status in biodegradable technology. The enhanced deliverability of BioMatrix NeoFlex™ does not compromise longitudinal or radial strength7, allowing delivery of our proprietary Limus drug BA9™ to even the most complex and difficult to reach lesions. This enhanced technical performance, and confidence from the results seen in the extensive clinical trial program, make the stent an excellent choice for your workhorse DES.

CHROMA

CHROMA™ is an innovation in stent design leading to outstanding performance. This Cobalt Chromium platform has been designed to address all your BMS needs - from everyday stenting to the more complex and challenging cases.

FEATURES

  • Innovative hybrid stent design
  • Cobalt Chromium
  • Thin struts (84/88 μm)
  • Advanced Stent Delivery System (SDS)

BENEFITS

  • Low recoil
  • Cell opening
  • Pushability, flexibility, trackability
  • Longitudinal strength